CEO, Co-Founder, Aepodia
Dr Gossen has over 20 years’ experience in pharmaceutical and biotechnological drug development. He received his PhD in Applied Biomedical Sciences from the Free University of Brussels (ULB, Belgium) and completed postdoctoral research as a Belgian American Educational Foundation Fellow (BAEF) at Tufts Medical Centre (formerly the New England Medical Centre) in Boston, Massachusetts. His research focused on the genetic regulatory mechanisms in the ontogeny of gastrointestinal hormones potentially involved in diabetes.
Dr Gossen joined the Eli Lilly Development Centre (Mont-Saint-Guibert, Belgium) as clinical researcher in 1994. He held positions of increasing responsibility in its clinical pharmacology department, where he served as clinical pharmacologist leading the early clinical development of new molecules.
He then joined the Therapeutic Neurosciences Group at UCB in Belgium as a research physician in charge of the clinical development of new molecules and line extensions of existing molecules.
When he returned to Eli Lilly, he was actively involved in the identification, development, and implementation of biomarkers, based on a proof-of-concept approach with a strong emphasis on preclinical/clinical translational research.
In 2007, Dr Gossen left Lilly to co-found Aepodia with Dr Demolle and other former colleagues and peers.